Advertisement
Advertisement
U.S. Markets open in 4 hrs 47 mins
Advertisement
Advertisement
Advertisement
Advertisement

ProtoKinetix, Incorporated (PKTX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0345+0.0045 (+15.00%)
At close: 02:56PM EDT
Advertisement
Sign in to post a message.
  • M
    Mark
    clarence smith, CEO of PKTX, is buying lots of stock at these prices. https://www.insider-analysis.com/search_transactions.php?ticker=TABLE_PKTX
  • G
    Gabrielle
    ⭐ Bullish Trade Ideas For 2022 👀🔥📈

    https://bullish-trades.com/top-trade-ideas
    Bullish
  • M
    Mark
    there were some insider transactions last week for large share amounts.
    https://newsfilter.io/articles/4-form-e6ffc577b38ad91af829a84cf7b6105b
  • M
    Mark
    RSI value is a really good predictor of a stock price bottom. This stock is near its dead low RSI .An uptick in volume usually precedes the RSI low. We've already begun to see that.
  • M
    Mark
    More shares trading today than during a given year. I wonder what's up with little or no price change.?
  • f
    fraser
    ***PKTX...ProtoKinetix AAGP(R) Retinal Cell Replacement Therapy Testing at UBC Completed

    MARIETTA, Ohio--(BUSINESS WIRE)--December 19, 2019--

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces the completion of an in vivo study to assess the effect of AAGP(R) on the long term survival and functional activity of photoreceptor precursor cells (PPCs) in the animal ocular model of genetic retinal degeneration.

    The objective of this study was to determine the effect of 24-hour pre-treatment with anti-aging glycoprotein (AAGP(R)) PKX-001 at 4 mg/mL on the long-term (3, 4.5 and 6 months) survival and functional activity of PPCs) following their subretinal transplantation into the eye of nude immunocompromised rats with genetic retinal degeneration.

    In vivo tests demonstrated that transplantation of PPCs pre-treated with AAGP(R) (PKX-001) results in statistically significant improvements in both the visual behavioral (optokinetic tracking test) and functional analysis (electroretinogram test) responses as compared with PPCs without pre-treatment.

    Imaging data revealed that pre-treatment of PPCs with AAGP(R) also leads to a substantial enhancement of cell survival as determined at 3, 4.5 and 6 months after cell transplantation. At the 6-month time point, the AAGP(R)-treated cells acquired the ability to express retinal and synaptic proteins, confirming that AAGP(R) has no adverse effect on precursor cells' maturation.

    Macular degeneration, or age-related macular degeneration (AMD), is a leading cause of vision loss in Americans 60 and older. It is a disease that destroys sharp, central vision. Central vision is crucial for seeing objects clearly and doing tasks such as reading and driving.

    AMD affects the macula, which is the part of the eye that allows you to see fine detail. AMD does not hurt, but it causes cells in the macula to die. There are two types of AMD: wet and dry. Wet AMD happens when abnormal blood vessels grow under the macula. These new blood vessels often leak blood and fluid. Wet AMD damages the macula quickly. Blurred vision is a common early symptom. Dry AMD happens when the light-sensitive cells in the macula slowly break down resulting in the loss of central vision.

    The study was conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.

    "AAGP(R) is proving itself to be a very useful pharmaceutical for markedly improving cell survival when transplanted into model systems. That this is important is proven by the functional benefits we are seeing in these models that would now warrant clinical trials." -- Dr. Kevin Gregory-Evans

    Dr. Kevin Gregory-Evans on ProtoKinetix AAGP(R)

    Dr. Gregory-Evans Bio

    The success of these tests opens doors for ProtoKinetix AAGP(R) in the entire field of regenerative medicine. The next step towards commercialization is partnering with a major pharma to adapt AAGP(R) into their current clinical trial program. The global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc.
    ProtoKinetix owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGP
    ProtoKinetix owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGP
    www.protokinetix.com
    Bullish
  • f
    fraser
    ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions

    Marietta, Ohio, May 12, 2020

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP® (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration.

    The ProtoKinetix-IQVIA collaboration will aim to accelerate the clinical development and regulatory progress of PKX-001. The collaboration is expected to drive directed clinical development as PKX-001 enters Phase 1 testing for the above conditions. This initiative will also serve to optimize these clinical trials to determine safety in these new conditions, drawing from previous experience with PKX-001 in Type 1 diabetes and other conditions.

    About IQVIA

    IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

    IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
    Bullish
  • f
    fraser
    ***PKTX..ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

    Marietta, Ohio, March 19, 2020
    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule.

    During recent testing conducted by EyeCRO of Oklahoma City, using a well-established animal model for Dry Eye Disease (DED), and Ocular Inflammation it was observed that AAGP® may have a substantial effect on the suppression and control of the disease. Based on these results the company has filed for patent protection with the United States Patent and Trademark Office (USPTO) for the application of DED. The patent application was submitted for both human and veterinary uses.

    Dry Eye Disease is one of the most common ocular problems with an estimated prevalence of almost 5-million people over the age of fifty in the United States alone. Current therapies for dry eye are palliative with a focus on the replacement of tears to reduce symptoms. Over-the-counter artificial tear formulations are available. Punctual palliative therapies are also available, and while they have benefits over the short term, they have limited utility in long-term control therapy for dry eye. Cyclosporine A is the first prescription product for dry eye therapy, which increases tear production in patients whose tear production is suppressed. However, Cyclosporine A treatment presents disadvantages over the long term which could potentially be mitigated by AAGP®.

    By protecting this technology, the Company is in a better position to move forward with its research in ophthalmological therapies.

    “Following the successful completion of recent testing of our AAGP® for dry eye disease, we need to ensure all our intellectual property is patented in order to protect its value.” - said Clarence E. Smith, president and chief executive officer.

    Please visit our new website at http://www.protokinetix.com for more information and to join our email list.
  • f
    fraser
    ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease

    Marietta, Ohio, November 23, 2021 - ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging Glycopeptide (AAGP®) product to be advanced into preclinical efficacy testing for the topical treatment of dry eye disease and ocular inflammation.

    The selection follows a seven-month formulation development program conducted by Catalent, in which the Active Pharmaceutical Ingredient (API) was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs. The efficacy testing will be conducted by EyeCRO of Oklahoma City. This study should be completed by mid to late January 2022. The resulting lead formulation will then undergo extensive Good Laboratory Practice (GLP) toxicology examination, to prepare a submission for the U.S. FDA for its approval to conduct clinical trials.

    “The relationship with Catalent has been extremely successful, and we believe this relationship will be ongoing for further development,” said Clarence E. Smith, President and Chief Executive Officer of ProtoKinetix. “This is a very exciting phase for the Company as it moves toward the commercialization phase in the Dry Eye Disease sector. The Company’s highest priority is to create stockholder value through the development and commercialization of products and delivery technology.”

    ProtoKinetix is working on staffing key personnel to achieve our growing deliverables. This work incorporates retention of highly specialized personnel to advance the Company's product commercialization plan. To secure regulatory approvals, this includes the execution of the required safety toxicology, clinical trials, and engagements. To achieve these goals, the Company is pleased to have expanded the roles of our advisor and consultant teams to add Dana Nohynek (Regulatory Affairs Consultant & Project Manager) and Christopher Santos (CMC Specialist), both specialists that continue to provide expertise, meeting Company needs for product development:

    Their expertise will be essential to the management of the production of ProtoKinetix’s AAGP® product and regulatory agency formulation toxicology requirements near term (which will continue to be guided by the Company’s expert Toxicologist Consultant, Evelina Rubinchik, PhD). Along with the Company executives and medical science advisors, these specialists will inform and maintain our commercialization plan and industry partnerships.

    Dry Eye Disease Market Overview
    According to market research published by Mordor Intelligence LLP, studies of the Dry Eye Disease market indicated a value of approximately USD 4.5 billion in 2018, and the market is expected to reach up to USD 6.2 billion by 2024, with an anticipated compound annual growth rate (CAGR) of 5.8%, during the forecast period (2020-2025). The growth of dry eye related diseases may include several factors, such as a significant increase in the population aged 65 and older, a decrease in the supportive hormones, systemic inflammatory diseases, ocular surfaces diseases or surgeries affecting the cholinergic nerves, which stimulate tear secretion.
    ProtoKinetix is leading the way in cell survival solutions. Its patented molecule, AAGP®, has the opportunity to shape tomorrow’s health therapies.
    ProtoKinetix is leading the way in cell survival solutions. Its patented molecule, AAGP®, has the opportunity to shape tomorrow’s health therapies.
    www.protokinetix.com
    Bullish
  • f
    fraser
    ***PKTX..ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials

    Marietta, Ohio, March 24, 2020

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020.

    ...We have now completed the sterilization, quality assurance, labeling of the AAGP® (PKX-001) and are ready to ship the final product to the University of Alberta upon receipt of the NOL from Health Canada for the continuation of the Phase 1 clinical trials.

    ...PKX-001 is the designation given to the lead drug product molecule of the AAGP® family. Islet cell transplants are well recognized as a viable and effective treatment for Type-1 diabetes. The PKX-001 study will treat islet cells prior to transplantation into human test subjects. The clinical trials primary objective is the establishment of patient safety. The study will also be making observations related to indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells. The trial follows extensive preclinical evaluation in experimental models (to learn more, refer to this link: Diabetes).

    ...The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.

    Dr. James Shapiro Bio

    Dr. James Shapiro Video

    About the Edmonton Protocol

    Diabetes Research Institue Foundation Canada Video

    To obtain additional information and updates regarding this trial please use the following link: Clinicaltrials.gov – Islet Transplantation Using PKX-001.

    See the promising research of AAGP® and results to date

    ***Visit our new website at ProtoKinetix.com for more information and to join our email list.
    COVID-19 Information as Applicable to ProtoKinetix

    ...In December 2019, the 2019 novel coronavirus (“COVID-19”) surfaced in Wuhan, China. The World Health Organization declared a global emergency on January 30, 2020, with respect to the outbreak and several countries, including the United States, Japan and Australia have initiated travel restrictions to and from China. The impacts of the outbreak are unknown and rapidly evolving.

    ...Although we rely on third-party suppliers and manufacturers in China to produce AAGP® for testing, we believe we have sufficient quantities to last the Company for the next two years. Nevertheless, this outbreak has resulted in the extended shutdown of certain businesses, which may in turn result in disruptions or delays to our supply chain and restrictions on the export or shipment of our products.

    ...Further, we cannot predict the availability of our scientists to continue testing or whether the trials can be completed. A widespread health crisis could adversely affect the global economy, resulting in an economic downturn that could impact demand for our products.

    ...To date the outbreak has not had a material adverse impact on our operations. However, the future impact of the outbreak is highly uncertain and cannot be predicted and there is no assurance that the outbreak will not have a material adverse impact on the future results of the Company. The extent of the impact, if any, will depend on future developments, including actions taken to contain COVID-19.
  • f
    fraser
    ProtoKinetix Takes Delivery of GMP AAGP(R) PKX-001 Dedicated for Phase 1 Trial
    8:30 AM ET 1/24/20 | BusinessWire

    MARIETTA, Ohio--(BUSINESS WIRE)--January 24, 2020--

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP(R)) molecule. We are shipping sufficient molecule to Iotron Industries in British Columbia for sterilization. The sterilization process is a 1-week turnaround. After sterilization there will be one more process needed that will take up to 3-weeks for quality assurance. The sterilized molecule will then be sent to the University of Alberta for use in the continuation of the Phase-1 first-in-human clinical trials of PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes. We are shipping ample molecule to include another 10-patients in the clinical trials. This represents the most significant scale-up of manufacturing in the Company's history. Upon receipt of the molecule, request for approval of the amendments will be submitted to Health Canada by the sponsor, the University of Alberta. This total process will take 4-6 weeks.

    The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.

    Dr. James Shapiro Bio

    Dr. James Shapiro Video

    About the Edmonton Protocol

    PKX-001 is the designation given to the lead drug product molecule of the AAGP(R) family. Islet cell transplants are well recognized as a viable and effective treatment for Type-1 diabetes. The PKX-001 study will treat islet cells prior to transplantation into human test subjects. The clinical trials primary objective is the establishment of patient safety. The study will also be making observations related to indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells. The trial follows extensive preclinical evaluation in experimental models (to learn more, refer to this link: Diabetes).

    To obtain additional information and updates regarding this trial please use the following link: Clinicaltrials.gov - Islet Transplantation Using PKX-001.
    ProtoKinetix owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGP
    ProtoKinetix owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGP
    www.protokinetix.com
  • f
    fraser
    ***PKTX...ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease

    Marietta, Ohio, April 6, 2020
    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX), a clinical-stage biomedical company, having recently announced filing for patent protection for new applications of its AAGP® (PKX-001) molecule, announces preliminary results in efficacy and safety for use in treating Dry Eye Disease (DED).

    PKX-001 demonstrates a protective effect in the murine model of dry eye disease. The effect of 5% PKX-001, delivered QID via bilateral topical administration, was evaluated in an acute murine model of desiccating stress (DS). The study was conducted by EyeCRO LLC (Oklahoma City, US). Corneal permeability was assessed by Oregon Green Dextran (OGD). CsA-MiDROPS™ significantly reduced DS-induced corneal permeability. PKX-001 reduced the DS-induced corneal permeability to the same level as the positive control CsA-MiDROPS. Additional tests are currently ongoing.

    PKX-001 has a favorable in vitro and in vivo safety profile. PKX-001 safety upon ocular administration was evaluated in two animal models. The first study was conducted by ITR Laboratories (Montreal, Canada). PKX-001 formulated in BSS at a concentration up to 10% was not considered an eye irritant.

    The second study was performed by EyeCRO LLC (Oklahoma City, US). Treated eyes were scored for chemosis, hyperemia and discharge on a daily basis. PKX-001 was well tolerated and not considered an eye irritant.

    Furthermore, PKX-001 was negative in the bacterial reverse mutation assay and did not induce chromosomal damage in the micronucleus test in animal model ovary cells (ITR laboratories, Montreal, Canada).

    PKX-001 demonstrated anti-inflammatory and cytoprotective properties:
    Reduced levels of anti-inflammatory cytokines
    Decreased oxidative stress
    Increased cellular survival and improved functional activity under various stress conditions

    “These positive results in efficacy and safety in the recent testing of our AAGP® for dry eye disease is extremely promising for the future of using our molecule to treat this disease.” - said Clarence E. Smith, President and Chief Executive Officer of ProtoKinetix. “We are currently planning to move forward with the next stages of development ourselves.”

    Market Overview
    According to market research published by Mordor Intelligence LLP, studies of the Dry Eye Disease market indicated a value of approximately USD 4.5 billion in 2018, and the market is expected to reach up to USD 6.2 billion by 2024, with an anticipated CAGR of 5.23%, during the forecast period (2019-2024). The growth of dry eye related diseases may include several factors, such as aging, a decrease in the supportive hormones, systemic inflammatory diseases, ocular surfaces diseases or surgeries affecting the cholinergic nerves, which stimulate tear secretion.

    Dry Eye Disease is one of the most common ocular problems with an estimated prevalence of almost five million people over the age of 50 in the United States alone. Cyclosporine A is the first prescription product for dry eye therapy, which increases tear production in patients whose tear production is suppressed. However, Cyclosporine A treatment presents disadvantages over the long term which could potentially be mitigated by AAGP®.

    Please visit our new website at ProtoKinetix.com for more information and to join our email list.
  • K
    K
    This stock can be described as providing the fuel needed for cell-based therapies in regenerative medicine. Many companies could licence it for their product lines that replace or repair tissues. Any company or health Center using biografts, stem cells or even whole organs can take advantage. Take any cell or tissue, add their peptide and it keep cells and grafts alive and thriving. They have a human clinical trial ongoing for diabetes to replace the insulin producing cells. Coming soon are the final stages of development to help replace retinas (a literal cure for blindness). Their peptide keeps cells alive and safe from harm caused by anti-rejection drugs during transplant. Imagine the possibilities for other organs. Now they are looking at developing approval strategies for second level applications, including eye drops (which might be useful after a retina transplant). On the business end, they have no debt (unusual in biotech plays), insider ownership is strong, and they utilize expert consultants, subcontracting, and specialty manufacturing firms to keep burn rates low. I am taking a long position with both stock and options.
    Bullish
  • f
    fraser
    ProtoKinetix AAGP® Dry Eye Therapy Testing Results
    Marietta, Ohio, January 6, 2020
    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to date have shown no sign of irritation.

    About ITR Laboratories

    Based on this ProtoKinetix is shipping AAGP® to EyeCRO to commence testing Dry Eye Disease efficacy. This testing will involve topical application of AAGP® and evaluations of its effects on ocular inflammation. EyeCRO is a world recognised, specialised CRO in the field of pre-clinical ocular drug research and development. This program will commence in early January 2020 and is expected to run for 3-4 months.

    About EyeCRO


    About Dry Eye Disease

    Dry Eye Disease is a condition in which a person does not have enough quality tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. Dry Eye Disease is a common and often chronic problem, particularly in older adults. This condition currently afflicts more that 30-million Americans (430-million people globally) and can affect as much as 40% of the population for various reasons. The dry eye disease ophthalmic market is very active, with $7.7 billion in revenues and a current growth of 12.5% CAGR.
    Bullish
  • f
    fraser
    ***PKTX...ProtoKinetix files for patent protection for the use of AAGP® in transplant medicine..
    Marietta, Ohio, February 11, 2020

    ....ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for a new application of its AAGP® molecule.

    During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP® may have had a role in protecting xenografts and allografts from immune rejection from the host immune system, thereby helping the graft to survive and mature in the transplant recipient.

    Immune rejection, leading to graft versus host disease (GVHD) is a primary concern present in almost all transplants, requiring the use of immunosuppressants such as cyclosporin, tacrolimus and rapamycin.

    In addition to filing for patent protection, ProtoKinetix has started a major study at Dalhousie University to examine the effects of AAGP® in transplant medicine.

    By protecting this technology, the Company is in a better position to move forward with its research in organ transplantation.

    “We are pleased to protect this patent as we can now license the rights to other companies to develop different applications of the AAGP® lead compound,” said Clarence E. Smith, president and chief executive officer.

    Please visit our new website at ProtoKinetix.com for more information and to join our email list.
    Bullish
  • M
    Mark
    People do have a tendency to buy high and sell low. Putin must be doing very well if he shorted the market a few weeks ago.
  • J
    Josh
    Bought all I could afford at these prices. I think this is a can’t miss. Patience required. Have no idea why people would be selling the stock at $.17 or $.18 a share? When this one moves I think it will move fast, especially if there’s a buyout. Holding long
  • T
    Tray
    ***News TODAY. This is going to EXPLODE within Time***

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of extensive testing, evidence of fully functional retinal cells was conclusively achieved. Based on these results Dr. Kevin Gregory-Evans shortly submitting a paper for publication in a peer reviewed journal.

    In vivo tests demonstrated that transplantation of PPCs pre-treated with AAGP® (PKX-001) results in statistically significant improvements in both the visual behavioral (optokinetic tracking test) and functional analysis (electroretinogram test) responses as compared with PPCs without pre-treatment. Imaging data revealed that pre-treatment of PPCs with AAGP® also leads to a substantial enhancement of cell survival as determined at 3, 4.5 and 6 months after cell transplantation. At the 6-month time point, the AAGP®-treated cells acquired the ability to express retinal and synaptic proteins, confirming that AAGP® has no adverse effect on precursor cells' maturation.

    Macular degeneration, or age-related macular degeneration (AMD), is a leading cause of vision loss in Americans 60 and older. It is a disease that destroys sharp, central vision. Central vision is crucial for seeing objects clearly and doing tasks such as reading and driving.

    AMD affects the macula, which is the part of the eye that allows you to see fine detail. AMD does not hurt, but it causes cells in the macula to die. There are two types of AMD: wet and dry. Wet AMD happens when abnormal blood vessels grow under the macula. These new blood vessels often leak blood and fluid. Wet AMD damages the macula quickly. Blurred vision is a common early symptom. Dry AMD happens when the light-sensitive cells in the macula slowly break down resulting in the loss of central vision.

    The study was conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.

    "We are very excited by these latest results showing functional benefits with these AAGP®-pre treated stem cells." – Dr. Kevin Gregory-Evans
    ProtoKinetix is leading the way in cell survival solutions. Its patented molecule, AAGP®, has the opportunity to shape tomorrow’s health therapies.
    ProtoKinetix is leading the way in cell survival solutions. Its patented molecule, AAGP®, has the opportunity to shape tomorrow’s health therapies.
    www.protokinetix.com
    Bullish
  • f
    fraser
    I hope everybody has been well..Just reminding you if you hadn't voted on PKTX's Proxy..Please do so before or on Feb., 10 2022

    ...I was told as a PKTX Investor..You will need to hold on to the control number, it will be a 16 Digit number..After you have voted to be able
    to attend the "Annual General Meeting of Protokinetix's Stockholders..Copy/Paste that number on the www.virtualshareholdermeeting.com/PKTX2022

    ***PKTX.. Remember Folks.... :+D

    Invitation letter for the 2021 Annual General Meeting of Shareholders
    (electronic meeting (e-AGM))

    ProtoKinetix, Inc.

    Friday February 11, 2022
    Meeting starts at 4:00p.m. EST

    You are cordially invited to attend, virtually, the Annual Meeting of Stockholders of ProtoKinetix, Incorporated (the “Company”) on February 11, 2022, at 4:00 p.m. Eastern Time, via webcast at www.virtualshareholdermeeting.com/PKTX2022 (the “Annual Meeting”).

    The Company arranges the 2022 Annual General Meeting of Shareholders
    in electronic meeting (e-AGM) format only without arranging any meeting rooms
    Online registration only to attend the meeting.

    This Annual General Meeting of Shareholders is an electronic meeting (e-AGM) to avoid the gathering of large
    numbers of people with high risk of spread of COVID-19 and provide convenience for shareholders to join the AGM via
    electronic meeting system without travelling to the meeting.
    Bullish
  • f
    fraser
    ***PKTX..ProtoKinetix AAGP® Dry Eye Program Advancing

    Marietta, Ohio, July 7, 2020
    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.

    Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will test AAGP® for treatments related to Dry Eye Disease. Proof of concept work and basic formulation have been completed.
    Current project updates are expected from the following:
    EyeCRO has been contracted to conduct confirmatory testing and dose ranging. Early progress reports from EyeCRO will be received over the next two weeks.
    Charles River have been contracted to conduct pilot toxicology studies, to start at the end of July 2020. Early stage indications are expected by mid-August 2020.
    Stability tests have been completed by Ambiopharm. The tests were conducted at room temperature, in a provisional formulation, under non-sterile conditions. These preliminary results are extremely encouraging.

    “We are pleased with the progress made with respect to the expansion of ProtoKinetix’s Dry Eye Disease program.” - said Clarence E. Smith, President and Chief Executive Officer of ProtoKinetix.
    Dry Eye Disease Market Overview
    According to market research published by Mordor Intelligence LLP, studies of the Dry Eye Disease market indicated a value of approximately USD 4.5 billion in 2018, and the market is expected to reach up to USD 6.2 billion by 2024, with an anticipated CAGR of 5.23%, during the forecast period (2019-2024). The growth of dry eye related diseases may include several factors, such as aging, a decrease in the supportive hormones, systemic inflammatory diseases, ocular surfaces diseases or surgeries affecting the cholinergic nerves, which stimulate tear secretion.
    Please visit our new website at ProtoKinetix.com for more information and to join our email list.
Advertisement
Advertisement